1. Home
  2. About ECDC
  3. Media centre
  4. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineArchived

ECDC comment

The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up.

Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S; for the CVT Vaccine Group. J Natl Cancer Inst. 2011 Sep 9. [Epub ahead of print]

Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest. The findings from Kreimer et al. need to be confirmed by other studies and require longer-term follow-up. However, if a one- or two-dose regimen of HPV vaccination does in fact elicit a good and durable immune response, these findings will have a great impact on costs and strategies for HPV vaccination programmes throughout Europe.

 

Related content